189265-97-2

Upstream product

• 159026-17-2 5-[(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-2-hydroxy-benzoic acid 
• 196505-69-8 C₂₇H₄₄O₆ 
• 128-13-2 ursodeoxycholic acid 
• 190335-32-1 5-[(R)-4-((3R,5R,7S,8R,9S,10S,13R,14S,17R)-7-Acetoxy-10,13-dimethyl-3-phosphonooxy-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-2-hydroxy-benzoic acid 

Downstream Products

• 89-57-6 5-Aminosalicylic Acid 

Relevant academic research and scientific papers

Basic studies on 5-(7-hydroxy-3-O-phosphonocholyl)aminosalicylic acid for the evaluation of microbial overgrowth

A newly synthesized conjugate of 7-hydroxy-3-O-phosphonocholic acid (ursodeoxycholic acid monophosphate) with 5-aminosalicylic acid (5-ASA-UDCA monophosphate) was investigated to determine its suitability for the evaluation of enteric bacteria. This compound, 5-ASA-UDCA monophosphate, was efficiently deconjugated by cholylglycine hydrolase to release 5-ASA, whereas it was completely resistant to deconjugation by pancreatic and intestinal mucosal enzymes. In everted gut sac experiments, 5-ASA-UDCA monophosphate was not actively absorbed from any part of the small intestine. In animal experiments, urinary excretions of N-acetyl-5-ASA (Ac-5ASA) were measured for 24 h following the oral administration of 20 mg of 5-ASA-U DCA monophosphate. Control rats excreted 276.3±89.0 μg (mean±S.E.) of Ac-5ASA, whereas the rats with intestinal bacterial overgrowth excreted more (1224.1 ± 231.5 μg; p0.01). These basic studies indicate that this compound is likely to offer a simple method for the evaluation of microbial overgrowth without the use of radioisotopes or expensive, special apparatus.